|
1.
|
|
18 p, 8.9 MB |
Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma
/
Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ;
Massó Vallés, Daniel (Vall d'Hebron Institut d'Oncologia) ;
Giuntini, Fabio (Vall d'Hebron Institut d'Oncologia) ;
González-Larreategui, Íñigo (Vall d'Hebron Institut d'Oncologia) ;
Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ;
Casacuberta-Serra, Sílvia (Vall d'Hebron Institut d'Oncologia) ;
Jauset, Toni (Vall d'Hebron Institut d'Oncologia) ;
Martínez-Martín, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ;
Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ;
Foradada Felip, Laia (Vall d'Hebron Institut d'Oncologia) ;
Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ;
Nonell, Lara (Vall d'Hebron Institut d'Oncologia) ;
Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Soucek, Laura (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway-the most predominantly mutated pathway in this disease-turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. [...]
2023 -  10.1101/gad.350078.122
Genes & Development, Vol. 37 (april 2023) , p. 303-320
|
|
|
2.
|
|
10 p, 912.2 KB |
Pharmacokinetic analysis of omomyc shows lasting structural integrity and long terminal half-Life in tumor tissue
/
Beaulieu, Marie-Eve (Peptomyc SL) ;
Martínez-Martín, Sandra (Peptomyc SL) ;
Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ;
Castillo Cano, Virginia (Peptomyc SL) ;
Massó Vallés, Daniel (Peptomyc SL) ;
Foradada Felip, Laia (Peptomyc SL) ;
López-Estévez, Sergio (Peptomyc SL) ;
Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ;
Thabussot, Hugo (Peptomyc SL) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. [...]
2023 - 10.3390/cancers15030826
Cancers, Vol. 15, Issue 3 (February 2023) , art. 826
|
|
|
3.
|
|
21 p, 11.5 MB |
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding
/
Massó Vallés, Daniel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Beaulieu, Marie-Eve (Hospital Universitari Vall d'Hebron) ;
Jauset González, Toni (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Giuntini, Fabio (Vall d'Hebron Institut d'Oncologia) ;
Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ;
Foradada Felip, Laia (Hospital Universitari Vall d'Hebron) ;
Martínez-Martín, Sandra (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Serrano, Erika (Vall d'Hebron Institut d'Oncologia) ;
Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ;
Casacuberta-Serra, Sílvia (Hospital Universitari Vall d'Hebron) ;
Castillo Cano, Virginia (Hospital Universitari Vall d'Hebron) ;
Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ;
López-Estévez, Sergio (Hospital Universitari Vall d'Hebron) ;
Morcillo, Miguel Ángel (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (Espanya)) ;
Alzrigat, Mohammad (Karolinska Institutet (Suècia). Department of Microbiology, Tumor and Cell Biology) ;
Mahmoud, Loay (Karolinska Institutet (Suècia). Department of Microbiology, Tumor and Cell Biology) ;
Luque-García, Antonio (Vall d'Hebron Institut d'Oncologia) ;
Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ;
Guzman, Marta (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Larsson, Lars-Gunnar (Karolinska Institutet (Suècia). Department of Microbiology, Tumor and Cell Biology) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Soucek, Laura (Institució Catalana de Recerca i Estudis Avançats)
While MYC role in metastasis has been long controversial, this manuscript demonstrates that MYC inhibition by either transgenic expression or pharmacologic use of the recombinantly produced Omomyc miniprotein exerts antitumor and antimetastatic activity in breast cancer models in vitro and in vivo, suggesting its clinical applicability.
2022 - 10.1158/2767-9764.CRC-21-0103
Cancer Research Communications, Vol. 2 (february 2022) , p. 110-130
|
|
|
4.
|
|
19 p, 1.3 MB |
Blocking Myc to treat cancer : reflecting on two decades of Omomyc
/
Massó Vallés, Daniel (Peptomyc S.L.) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. [...]
2020 - 10.3390/cells9040883
Cells, Vol. 9, Issue 4 (April 2020) , art. 883
|
|
|
5.
|
|
10 p, 3.3 MB |
The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets
/
Zacarías-Fluck, Mariano F. (Vall d'Hebron Institut d'Oncologia) ;
Jauset González, Toni (Hospital Universitari Vall d'Hebron) ;
Martínez-Martín, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ;
Casacuberta-Serra, Sílvia (Hospital Universitari Vall d'Hebron) ;
Massó Vallés, Daniel (Vall d'Hebron Institut d'Oncologia) ;
Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ;
Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ;
González-Larreategui, Íñigo (Vall d'Hebron Institut d'Oncologia) ;
López-Estévez, Sergio (Hospital Universitari Vall d'Hebron) ;
Brown-Swigart, Lamorna (Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California) ;
Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Madan, Babita (Program in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School) ;
Virshup, David M. (Program in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School) ;
Evan, Gerard I (Department of Biochemistry, University of Cambridge) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Zacarías-Fluck, et al identify and validate the Wnt receptor Fzd9 as a key effector of Myc-Wnt signaling cross-talk in a mouse model of Myc-driven pancreatic insulinomas. The huge cadre of genes regulated by Myc has obstructed the identification of critical effectors that are essential for Myc-driven tumorigenesis. [...]
2021 - 10.26508/lsa.201900490
Life Science Alliance, Vol. 4 (march 2021)
|
|
|
6.
|
|
13 p, 5.3 MB |
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
/
Jauset González, Toni (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Massó Vallés, Daniel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Martínez Martín, Sandra (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ;
Foradada Felip, Laia (Vall d'Hebron Institut d'Oncologia) ;
Fiorentino, Francesco Paolo (Department of Biomedical Sciences, University of Sassari) ;
Yokota, Jun (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Haendler, Bernard (Drug Discovery, Bayer AG) ;
Siegel, Stephan (Drug Discovery, Bayer AG) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Effectively treating KRAS-driven tumors remains an unsolved challenge. The inhibition of downstream signaling effectors is a way of overcoming the issue of direct targeting of mutant KRAS, which has shown limited efficacy so far. [...]
2018 - 10.18632/oncotarget.24648
Oncotarget, Vol. 9 (april 2018) , p. 18734-18746
|
|
|
7.
|
|
168 p, 6.5 MB |
Inhibiting Myc and the Myc dependent inflammatory response as cancer therapies
/
Massó Vallés, Daniel ;
Soucek, Laura, dir. ;
Arribas, Joaquín V., , dir. (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona.
Departament de Bioquímica i de Biologia Molecular
Aquesta tesi s'ha realitzat al Laboratori de Modelització de Teràpies Anti-tumorals en Ratolí dirigit per la Dra. Laura Soucek al Programa de Recerca Preclínica del Vall d'Hebron Institut d'Oncologia (VHIO), i comprèn dos projectes diferenciats centrats en dues de les funcions oncogèniques de Myc. [...]
The work of this thesis was carried out in the Mouse Models of Cancer Therapies Laboratory led by Dr. Laura Soucek in the Preclinical Research Program of the Vall d'Hebron Institute of Oncology (VHIO), and comprises two differentiated parts centered on two oncogenic functions of Myc. [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2017.
|
|
|
8.
|
|
|
9.
|
|
11 p, 1.8 MB |
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
/
Annibali, Daniela (University of California) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Favuzzi, Emilia (Università La Sapienza) ;
Jauset González, Toni (Universitat Autònoma de Barcelona) ;
Serrano, Erika (Universitat Autònoma de Barcelona) ;
Cuartas, Isabel (Universitat Autònoma de Barcelona) ;
Redondo Campos, Sara (Universitat Autònoma de Barcelona) ;
Folch, Gerard (Universitat Autònoma de Barcelona) ;
Gonzàlez-Juncà, Alba (Universitat Autònoma de Barcelona) ;
Sodir, Nicole M. (University of Cambridge) ;
Massó Vallés, Daniel (Universitat Autònoma de Barcelona) ;
Beaulieu, Marie-Eve (Universitat Autònoma de Barcelona) ;
Swigart, Lamorna B. (University of California) ;
Mc Gee, Margaret M. (University College Dublin) ;
Somma, Maria Patrizia (Università La Sapienza) ;
Nasi, Sergio (Università La Sapienza) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats) ;
Evan, Gerard I. (University of Cambridge) ;
Soucek, Laura (Universitat Autònoma de Barcelona)
Gliomas are the most common primary tumours affecting the adult central nervous system and respond poorly to standard therapy. Myc is causally implicated in most human tumours and the majority of glioblastomas have elevated Myc levels. [...]
2014 - 10.1038/ncomms5632
Nature communications, Vol. 5 (August 2014) , art. 4632
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
